Abstract:The last decade saw impressive advances not only in the discovery of gene mutations causing epilepsy, but also in unraveling the molecular mechanisms underlying the clinical manifestations of the disease. Increasing evidence is emerging that understanding these mechanisms is relevant for selection of the most appropriate treatment in the affected individual(s). The present article discusses the therapeutic implications of epilepsy-causing variants affecting a broad range of targets, from ion channels to genes controlling cellular metabolism and cell signaling pathways. Identification of a precise genetic etiology can direct physicians to (i) prescribe treatments that correct specific metabolic defects (e.g., the ketogenic diet for GLUT1 deficiency, or pyridoxine for pyridoxine-dependent epilepsies); (ii) avoid antiepileptic drugs (AEDs) that can aggravate the pathogenic defect (e.g., sodium channel blocking drugs in SCN1A-related Dravet syndrome), or (iii) select AEDs that counteract the functional disturbance caused by the gene mutation (e.g., sodium channel blockers for epilepsies due to gain-of-function SCN8A mutations). In some instances, different pathogenic variants of the same gene can have opposite functional effects, which determines whether certain treatments can be beneficial or deleterious (e.g., gain-of-function versus loss-of-function variants in SCN2A determine whether sodium channel blockers improve or worsen seizure control). There are also cases where functional disturbances caused by the gene defect may not be corrected by existing AEDs, but can be countered by medications already available in the market for other indications (e.g., memantine has been used to treat the epileptic encephalopathy caused by a specific gain-of-function GRIN2A mutation), thus making 'drug repurposing' a valuable tool for personalized epilepsy therapies. As our understanding of pathogenic mechanisms improve, opportunities arise for development of treatments targeting the specific gene defect or its consequences. Everolimus, an mTOR inhibitor approved for the treatment of focal seizures associated with tuberous sclerosis complex, is an example of a medication targeting the etiological mechanisms of the disease. Several treatments aimed at correcting specific pathogenic defects responsible for rare genetic epilepsies are currently in development, and range from traditional small molecules to novel approaches involving peptides, antisense oligonucleotides, and gene therapy.

A Prime Example of the Role of Precision Medicine in Genetic Epilepsy

Clinical and Molecular Analysis of Epilepsy-Related Genes in Patients with Dravet Syndrome

Dravet syndrome with favourable cognitive and behavioral development due to a novel SCN1A frameshift mutation

Dravet syndrome and its mimics: Beyond SCN1A

Do All Roads Lead to Rome? Genes Causing Dravet Syndrome and Dravet Syndrome-Like Phenotypes

Advancements in Dravet Syndrome Therapeutics: A Comprehensive Look at Present and Future Treatment Horizons: A Focused Review

Therapeutic advances in Dravet syndrome: a targeted literature review

The Current Precision Medicine Approaches in Genetic Epilepsies

Genetic Advancements in Infantile Epileptic Spasms Syndrome and Opportunities for Precision Medicine

Widespread genomic influences on phenotype in Dravet syndrome, a 'monogenic' condition

Study on the causative genes and analysis of genotypes and phenotypes of Dravet syndrome

Clinical-electroencephalogram characteristics and its evolutionary process of Dravet syndrome

Identifying mutations in epilepsy genes: Impact on treatment selection

Dravet syndrome as part of the clinical and genetic spectrum of sodium channel epilepsies and encephalopathies

Prognosis and follow-up study of 670 pediatric patients with Dravet syndrome

Epigenetic insights into GABAergic development in Dravet Syndrome iPSC and therapeutic implications

Exome sequencing identifies molecular diagnosis in children with drug-resistant epilepsy

Importance of targeted next-generation sequencing in pediatric patients with developmental epileptic encephalopathy

Genetic Testing in Children with Developmental and Epileptic Encephalopathies: A Review of Advances in Epilepsy Genomics

Unraveling Dravet Syndrome: Exploring the complex effects of sodium channel mutations on neuronal networks

Early Clinical Features and Diagnosis of Dravet Syndrome in 138 Chinese Patients with SCN1A Mutations